The number of people who intend to get vaccinated for COVID-19, or who have already received a vaccine for the disease, has risen to 88%, according to the results of the latest tracker survey by Ipsos MRBI for the Irish Pharmaceutical Healthcare Association (IPHA) which represents the international research-based biopharmaceutical industry.
The results show 63% of people will take a COVID-19 vaccine. But when combined with the vaccinated cohort, or 26% of the sample*, that number rises to 88% – 13 points higher than the percentage of people who said in January that they would take a COVID-19 vaccine.
Between January and May, the number of people who said they either won’t get vaccinated for COVID-19 or were unsure about taking a vaccine has declined. In January, 7% said they would refuse a COVID-19 vaccine and 18% were unsure. This month, 4% overall say they will refuse a COVID-19 vaccine and 7% are unsure.
The results come as the industry calls for global collaborative efforts to step up responsible COVID-19 vaccine dose-sharing and maximise production without compromising quality or safety.
Bernard Mallee, Director of Communications and Advocacy at IPHA, said: “It is clear that vaccination is helping to contain the disease, with indicators across mortality, hospitalisations, ICU admissions and caseload stabilising or decreasing. That is enabling the country to gradually unlock. The health authorities deserve much credit for the speed and efficiency with which they have managed the vaccination programme.
“With vaccines-makers investing in their own sites and forming almost 300 partnerships and collaborations globally, production has risen in just a few months from zero to 2.2 billion COVID-19 vaccine doses by the end of this month. As well as bringing forward COVID-19 vaccine breakthroughs in record time, the industry is surging production to meet global demand. By the end of this year, analysts are predicting 11 billion COVID-19 vaccine doses will have been produced – enough doses to vaccinate the world’s adult population.
“But where governments have significant domestic supplies of COVID-19 vaccine doses, they should share a meaningful proportion of them with low and lower middle-income countries. At the same time, innovators in our industry are working hard to generate responses for variants of concern – an illustration of the importance of protecting intellectual property rights, the formula for scientific invention.”
